Israel - English - Ministry of Health

taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 1000 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 140 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 50 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 70 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 80 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with:* newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - bortezomib is indicated for the treatment of patients with multiple myeloma.bortezomib is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.